Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Amarantus Bioscience Holdi AMBS
(Total Views: 410)
Posted On: 05/30/2018 3:03:17 PM
Post# of 30067
Avatar
Posted By: zoomboom
Dr. Michael T. Ropacki, newly-appointed Chief Medical Advisor for the Alzheimer's Blood Diagnostic LymPro Test program. "The Food and Drug Administration's recently released draft guidance on Early Alzheimer's disease drug development reflects their current thinking on patient and clinical endpoint selection, as well as patient staging. This draft guidance emphasized the role that biomarkers play in the reliable identification and potential stratification of patients, as well as how biomarker changes may, in principle, serve as the basis for accelerated approval. This provides a unique opportunity, as LymPro has the potential to help fulfill the need for a reliable and cost-effective blood-based biomarker for patient identification and may also provide needed evidence on biomarker change over time."













(8)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site